de Velasco G., Alonso-Gordoa T., Rodríguez-Vida A., Anguera G., Campayo M., Pinto Á., Ortega E.M., Gallardo E., Núñez N.F., García-Carbonero I., Reig O., Méndez-Vidal M.J., Fernández-Calvo O., Cassinello N.V., Torregrosa D., López-Martín A., Rosero A., Valiente P.G., de España C.G., Climent M.A., Santasusana M.D., Sánchez Á.R., González I.C., Afonso R., García del Muro X., Casinello J., Fernández-Parra E.M., García Sánchez L., Afonso J., Polo S.H., Asensio Ú.. Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib. Clinical Genitourinary Cancer. 2023; 21(3)DOI:10.1016/j.clgc.2022.11.021. PMID:36610891. IF:2.300(Q2/5D).

Roldan-Romero, JM, Valdivia, C, Santos, M, Lanillos, J, Maroto, P, Anguera, G, Calsina, B, Martinez-Montes, A, Monteagudo, M, Mellid, S, Leandro-Garcia, LJ, Montero-Conde, C, Cascon, A, Roncador, G, Coloma, J, Robledo, M, Rodriguez-Antona, C. Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition. INTERNATIONAL JOURNAL OF CANCER. 2023; 153(6)DOI:10.1002/ijc.34575. PMID:37260183. IF:5.700(Q1/2D).

Kobel, M, Kang, EY, Weir, A, Rambau, PF, Lee, CH, Nelson, GS, Ghatage, P, Meagher, NS, Riggan, MJ, Alsop, J, Anglesio, MS, Beckmann, MW, Bisinotto, C, Boisen, M, Boros, J, Brand, AH, Brooks-Wilson, A, Carney, ME, Coulson, P, Courtney-Brooks, M, Cushing-Haugen, KL, Cybulski, C, Deen, S, El-Bahrawy, MA, Elishaev, E, Erber, R, Fereday, S, Fischer, A, Gayther, SA, Barquin-Garcia, A, Gentry-Maharaj, A, Gilks, CB, Gronwald, H, Grube, M, Harnett, PR, Harris, HR, Hartkopf, AD, Hartmann, A, Hein, A, Hendley, J, Hernandez, BY, Huang, YJ, Jakubowska, A, Jimenez-Linan, M, Jones, ME, Kennedy, CJ, Kluz, T, Koziak, JM, Lesnock, J, Lester, J, Lubinski, J, Longacre, TA, Lycke, M, Mateoiu, C, McCauley, BM, McGuire, V, Ney, B, Olawaiye, A, Orsulic, S, Osorio, A, Paz-Ares, L, Cajal, TRY, Rothstein, JH, Ruebner, M, Schoemaker, MJ, Shah, MT, Sharma, R, Sherman, ME, Shvetsov, YB, Singh, N, Steed, H, Storr, SJ, Talhouk, A, Traficante, N, Wang, C, Whittemore, AS, Widschwendter, M, Wilkens, LR, Winham, SJ, Benitez, J, Berchuck, A, Bowtell, DD, dos Reis, FJC, Campbell, I, Cook, LS, DeFazio, A, Doherty, JA, Fasching, PA, Fortner, RT, Garcia, MJ, Goodman, MT, Goode, EL, Gronwald, J, Huntsman, DG, Karlan, BY, Kelemen, LE, Kommoss, S, Le, ND, Martin, SG, Menon, U, Modugno, F, Pharoah, PDP, Schildkraut, JM, Sieh, W, Staebler, A, Sundfeldt, K, Swerdlow, AJ, Ramus, SJ, Brenton, JD. p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study. Journal of Pathology Clinical Research. 2023; 9(3)DOI:10.1002/cjp2.311. PMID:36948887. IF:3.400(Q1/3D).

Remon, J, Besse, B, Aix, SP, Callejo, A, Al-Rabi, K, Bernabe, R, Greillier, L, Majem, M, Reguart, N, Monnet, I, Cousin, S, Garrido, P, Robinet, G, Campelo, RG, Madroszyk, A, Mazieres, J, Curcio, H, Wasag, B, Pretzenbacher, Y, Fournier, B, Dingemans, AMC, Dziadziuszko, R. Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial. ANNALS OF ONCOLOGY. 2023; 34(5)DOI:10.1016/j.annonc.2023.02.012. PMID:36863484. IF:56.700(Q1/1D).

Lozano, R, Castro, E, -Campos, FL, Thorne, H, Ramirez-Backhaus, M, Aragon, IM, Cendon-Florez, Y, Gutierrez-Pecharroman, A, Salles, DC, Romero-Laorden, N, Lorente, D, Gonzalez-Peramato, P, Calatrava, A, Alonso, C, Anido, U, Arevalo-Lobera, S, Balmana, J, Chirivella, I, Juan-Fita, MJ, Llort, G, Cajal, TRY, Almagro, E, Alameda, D, Lopez-Casas, PP, Herrera, B, Mateo, J, Pritchard, CC, Antonarakis, ES, Lotan, TL, Rubio-Briones, J, Sandhu, S, Olmos, D. Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers. EUROPEAN JOURNAL OF CANCER. 2023; 185DOI:10.1016/j.ejca.2023.02.022. PMID:36972661. IF:7.600(Q1/2D).

Sanfilippo, R, Hindi, N, Jurado, JC, Blay, JY, Lopez-Pousa, A, Italiano, A, Alvarez, R, Gutierrez, A, Rincon-Perez, I, Sangalli, C, Aguiar, JLP, Romero, J, Morosi, C, Sunyach, MP, Fabbroni, C, Romagosa, C, Ranchere-Vince, D, Dei Tos, AP, Casali, PG, Martin-Broto, J, Gronchi, A. Effectiveness and Safety of Trabectedin and Radiotherapy for Patients With Myxoid Liposarcoma A Nonrandomized Clinical Trial. JAMA Oncology. 2023; 9(5)DOI:10.1001/jamaoncol.2023.0056. PMID:36995731. IF:22.300(Q1/1D).

Martinez-Bosch, N, Vilarino, N, Alameda, F, Mojal, S, Arumi-Uria, M, Carrato, C, Aldecoa, I, Ribalta, T, Vidal, N, Bellosillo, B, Menendez, S, Del Barco, S, Gallego, O, Pineda, E, Lopez-Martos, R, Hernandez, A, Mesia, C, Esteve-Codina, A, de la Iglesia, N, Balana, C, Martinez-Garcia, M, Navarro, P. Gal-1 Expression Analysis in the GLIOCAT Multicenter Study: Role as a Prognostic Factor and an Immune-Suppressive Biomarker. Cells. 2023; 12(6)DOI:10.3390/cells12060843. PMID:36980184. IF:5.100(Q2/4D).

Chmielecki, J, Gray, JE, Cheng, Y, Ohe, Y, Imamura, F, Cho, BC, Lin, MC, Majem, M, Shah, R, Rukazenkov, Y, Todd, A, Markovets, A, Barrett, JC, Hartmaier, RJ, Ramalingam, SS. Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer. Nature Communications. 2023; 14(1)DOI:10.1038/s41467-023-35961-y. PMID:36849494. IF:14.700(Q1/1D).